Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2021 | Should every myeloma patient receive first-line daratumumab?

Fredrik Schjesvold • 1 Apr 2021
ESH MM 2021
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide Thalidomide

Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, shares his views on whether all patients with multiple myeloma should be treated with daratumumab in the first line at ESH MM 2021. Dr Schjesvold highlights variations in daratumumab efficacy in different patient subgroups and outlines the risks of complications. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

More from Fredrik Schjesvold

1:29
Replacing dexamethasone in transplant-ineligible multiple myeloma: the REST study
Fredrik Schjesvold • 11 Dec 2023
1:21
The REMNANT study: will treating patients at MRD relapse improve survival outcomes?
Fredrik Schjesvold • 11 Dec 2023
1:38
A Phase I study of WVT078, a BCMA×CD3 bsAb, with a gamma-secretase inhibitor (WHG626) in R/R MM
Fredrik Schjesvold • 11 Dec 2023
1:23
Melflufen/dex versus pom/dex in patients with R/R multiple myeloma without previous transplant
Fredrik Schjesvold • 11 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals